Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy|
|Authors: ||BOSETTI, Rita|
|Issue Date: ||2014|
|Citation: ||NANOMEDICINE, 9 (14), p. 2175-2186|
|Abstract: ||This article examines the cost-effectiveness of chemotherapy (gemcitabine) versus nanotherapy (PEGylated liposomal doxorubicin) in the treatment of ovarian cancer. Significant differences in costs were mainly due to the initial drug costs, which were €1285.28 in favor of chemotherapy. These costs were more than offset by hospitalization costs, which were €2670.21 in favor of the nanotherapy. The cost per quality-adjusted life week (QALW) for the nanotherapy was estimated to be €220.92/QALW for the base case and ranged from €170-318/QALW based on model assumptions. The clinical benefit associated with nanotherapy was achieved, yielding not only positive cost-effectiveness results, but also, surprisingly, financial savings. Although more studies are necessary, this first comprehensive analysis supports the further use of nanotherapy for ovarian cancer.|
|Notes: ||Bosetti, R (reprint author), Hasselt Univ, Dept Appl Econ, Martelarenlaan 42 BE3500, Hasselt, Belgium.
|Link to publication: ||http://www.ncbi.nlm.nih.gov/pubmed/25405795|
|ISI #: ||000345285700010|
|Type: ||Journal Contribution|
|Validation: ||ecoom, 2015|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.